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Abstract
Background  and  objectives:  Esmolol  is  known  to  have  no  analgesic  activity  and  no  anaesthetic
properties;  however,  it  could  potentiate  the  reduction  in  anaesthetic  requirements  and  reduce
postoperative  analgesic  use.  The  objective  of  this  study  is  to  evaluate  the  effect  of  intravenous
esmolol  infusion  on  intraoperative  and  postoperative  analgesic  consumptions  as  well  as  its  effect
on  depth  of  anaesthesia.
Methods: This  randomized-controlled  double  blind  study  was  conducted  in  a  tertiary  care  hospi-
tal  between  March  and  June  2010.  Sixty  patients  undergoing  septorhinoplasty  were  randomized
into  two  groups.  History  of  allergy  to  drugs  used  in  the  study,  ischaemic  heart  disease,  heart
block,  bronchial  asthma,  hepatic  or  renal  dysfunction,  obesity  and  a  history  of  chronic  use  of
analgesic  or  -blockers  were  considered  cause  for  exclusion  from  the  study.  Thirty  patients
received  esmolol  and  remifentanil  (esmolol  group)  and  30  patients  received  normal  saline  and
remifentanil  (control  group)  as  an  intravenous  infusion  during  the  procedure.  Mean  arterial
pressure,  heart  rate,  and  bispectral  index  values  were  recorded  every  10  min.  Total  remifen-
tanil  consumption,  visual  analogue  scale  scores,  time  to  ﬁrst  analgesia  and  total  postoperative
morphine  consumption  were  recorded.
Results: The  total  remifentanil  consumption,  visual  analogue  scale  scores  at  0,  20  and  60  min,
total  morphine  consumption,  time  to  ﬁrst  analgesia  and  the  number  of  patients  who  needed  an
intravenous  morphine  were  lower  in  the  esmolol  group.
Conclusions:  Intravenous  infusion  of  esmolol  reduced  the  intraoperative  and  postoperative
analgesic consumption,  reduced  visual  analogue  scale  scores  in  the  early  postoperative  period
and  prolonged  the  time  to  ﬁrst  analgesia;  however  it  did  not  inﬂuence  the  depth  of  anaesthesia.
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Índice  bispectral;
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Infusão  intraoperatória  de  esmolol  reduz  o  consumo  pós-operatório  de  analgésicos  e
o uso  de  anestésico  durante  a  septorrinoplastia:  estudo  randômico
Resumo
Justiﬁcativa  e  objetivos:  esmolol  é  conhecido  por  não  ter  atividade  analgésica  e  propriedades
anestésicas;  porém,  pode  potenciar  a  reduc¸ão  da  necessidade  de  anestésicos  e  reduzir  o  uso
de  analgésicos  no  pós-operatório.  O  objetivo  deste  estudo  foi  avaliar  o  efeito  da  infusão  de
esmolol  por  via  intravenosa  sobre  o  consumo  de  analgésico  durante  os  períodos  intraoperatório
e  pós-operatório,  bem  como  seu  efeito  sobre  a  profundidade  da  anestesia.
Métodos: este  estudo  randômico,  controlado  e  duplo-cego  foi  conduzido  em  um  hospital  ter-
ciário  entre  marc¸o e  junho  de  2010.  Foram  randomicamente  divididos  em  dois  grupos  60
pacientes  programados  para  serem  submetidos  à  septorrinoplastia.  História  de  alergia  aos
medicamentos  usados  no  estudo,  isquemia  cardíaca,  bloqueio  cardíaco,  asma  brônquica,  insuﬁ-
ciência  hepática  ou  renal,  obesidade  e  história  de  uso  crônico  de  analgésicos  ou  -bloqueadores
foram  os  critérios  de  exclusão.  Trinta  pacientes  receberam  esmolol  e  remifentanil  (grupo
esmolol)  e  30  receberam  soro  ﬁsiológico  e  remifentanil  (grupo  controle)  via  perfusão  intra-
venosa.  Pressão  arterial  média,  frequência  cardíaca  e  valores  do  índice  bispectral  foram
registrados  a  cada  10  minutos.  Consumo  total  de  remifentanil,  escores  da  escala  visual  analóg-
ica,  tempo  para  a  primeira  analgesia  e  consumo  total  de  morﬁna  no  pós-operatório  foram
registrados.
Resultados:  o  consumo  total  de  remifentanil,  os  escores  da  escala  visual  analógica  nos  minu-
tos 0,  20  e  60,  o  consumo  total  de  morﬁna,  o  tempo  para  a  primeira  analgesia  e  o  número  de
pacientes  que  precisaram  de  morﬁna  intravenosa  foram  menores  no  grupo  esmolol.
Conclusões: esmolol  em  infusão  intravenosa  reduziu  o  consumo  de  analgésicos  tanto  no
intraoperatório quanto  no  pós-operatório,  reduziu  os  escores  da  escala  analógica  visual  no  pós-
operatório  imediato  e  prolongou  o  tempo  para  a  primeira  analgesia;  contudo,  não  inﬂuenciou
a  profundidade  da  anestesia.
© 2014  Sociedade  Brasileira  de  Anestesiologia.  Publicado  por  Elsevier  Editora  Ltda.  
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smolol  is  an  ultra-short-acting,  cardioselective  1-receptor
ntagonist. It  is  effective  in  blunting  adrenergic  responses  to
erioperative stimuli,  including  tracheal  intubation,1 intra-
perative  events  caused  by  decreasing  anaesthetic  depth,2
nd  tracheal  extubation.3 Esmolol  is  known  to  have  no
nalgesic activity  and  no  anaesthetic  properties.4 However,
revious studies  have  shown  that  esmolol  could  potentiate
he reduction  in  anaesthetic  requirements  during  propofol,5
r  volatile-based  anaesthesia.6 In  a  previous  study  it  was
uggested that  esmolol  infusion  reduced  the  intraoperative
se of  fentanyl,  decreased  haemodynamic  responses  and
educed postoperative  morphine  consumption.7 Esmolol  also
ecreased nociception  in  a  variety  of  experimental  settings,
uggesting the  potential  to  decrease  the  intraoperative
naesthetic requirements.8 In  animals  esmolol  provided
nalgesia and  a  reduction  of  cardiovascular  responses  to
ain in  the  absence  of  anaesthesia.9 However  the  role  of
smolol in  pain  modulation  remains  to  be  established.This  prospective,  randomized,  double-blind,  placebo
ontrolled study  was  designed  to  assess  the  effect  of  peri-
perative esmolol  upon  analgesic  consumption  and  depth  of
naesthesia in  patients  undergoing  septorhinoplasty  surgery.
s
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cethods
atients
fter  approval  by  the  Institutional  Ethics  Committee,
atients’ written  informed  consents  were  obtained.  The
tudy took  place  in  a  tertiary  hospital  between  March  and
une 2010.  Patients  of  American  Society  of  Anesthesiologists
ASA) physical  status  I--II,  ages  18--65  years  old  and  under-
oing septorhinoplasty  were  enrolled  in  this  study.  Patients
ere selected  randomly  by  using  computer-generated  ran-
om numbers  and  divided  into  two  groups  (esmolol  vs.
ontrol). Exclusion  criteria  included  allergic  history  to  any
f the  drugs  used  in  the  study,  ischaemic  heart  disease,
eart block,  bronchial  asthma,  hepatic  or  renal  dysfunc-
ion and  obesity  (body  mass  index  ≥  30)  and  a  history  of
hronic use  of  analgesic  or  -blocking  agents.  No  patients
ere excluded  from  the  study  according  to  these  criteria.
atient recruitment  to  the  study  was  started  upon  calcula-
ion of  the  sample  size  using  the  University  of  Iowa’s  sample
ize calculator.  At  95%  conﬁdence  level  (1  −  ˛)  and  power
1 −  ˇ)  of  80%,  ratio  of  cases  to  control  1:1,  we  enrolled  30
ases for  the  study  group  while  30  cases  were  required  as
ontrols.
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Anaesthesia
All  patients  were  informed  about  the  visual  analogue  scale
(VAS; 0 =  no  pain,  10  =  worst  imaginable  pain),  the  verbal
rating scale  (VRS;  0  =  no  pain,  1  =  weak  pain,  2  =  moderate
pain, 3  =  severe  pain,  4  =  excruciating  pain)  and  the  patient-
controlled IV  analgesia  device  before  surgery.  Patients  were
not  premedicated  before  surgery.  All  patients  were  mon-
itored with  bispectral  index  (BIS)  in  addition  to  standard
monitorization.
Patients in  the  esmolol  group  received  a  loading  dose  of
esmolol (0.5  mg  kg−1 in  30  mL  normal  saline)  followed  by  an
infusion of  esmolol  (0.05  mg  kg−1 min−1)  while  patients  in  the
control group  received  the  same  volume  of  normal  saline  for
loading dose  and  continuous  infusion.
General  anaesthesia  was  induced  in  all  patients  with
propofol (2.5  mg  kg−1)  and  a  mixture  of  oxygen  and  air
(50--50%). After  induction,  an  infusion  of  remifentanil
(0.05--0.5 g  kg−1 min−1)  was  started  in  both  groups.  Vecuro-
nium bromide  (0.1  mg  kg−1)  was  administered  to  maintain
muscle relaxation  and  for  tracheal  intubation.  Sevoﬂurane
at an  end-tidal  concentration  of  2  MAC  in  air/oxygen  mixture
was used  for  the  maintenance  of  anaesthesia.  To  deter-
mine the  depth  of  anaesthesia,  BIS  monitoring  was  used
in addition  to  autonomic  or  somatic  signs  and  changes  in
mean arterial  pressure  (MAP)  or  heart  rate  (HR).  A  BIS  value
between 40  and  60  was  targeted  since  it  was  accepted
as an  adequate  level  of  anaesthesia  at  which  recall  was
prohibited.10
The  depth  of  anaesthesia  was  assessed.  (1)  An  increase
in MAP  and  HR  of  more  than  20%  from  baseline  for  more
than 1  min;  (2)  autonomic  signs  (e.g.  mydriasis,  ﬂushing,
lacrimation); (3)  somatic  signs  (e.g.  purposeful  eye  move-
ments, grimacing,  swallowing);  and  (4)  BIS  values  greater
than 60  were  considered  as  inadequate  depth  of  anaes-
thesia. The  remifentanil  dose  was  titrated  to  increase  the
depth of  anaesthesia  in  the  presence  of  at  least  one  of  these
signs. Data  were  recorded  1  min  before  induction,  immedi-
ately after  induction,  1,  3  and  5  min  after  intubation  and
at 10  min  intervals  during  surgery.  During  surgery,  the  qual-
ity of  the  surgical  ﬁeld  was  evaluated  every  10  min  by  the
same surgeon,  who  was  blinded  to  the  study,  using  an  eval-
uation scale  for  bleeding  of  the  surgical  ﬁeld  (Table  1).  At
the completion  of  surgery,  all  infusions  were  discontinued.
Table  1  Evaluation  scale  for  bleeding  of  surgical  ﬁeld.
0  No  bleeding
1 Slight  bleeding  --  no  suctioning  of  blood  required
2  Slight  bleeding  --  occasional  suctioning  required.  Surgical
ﬁeld  not  threatened
3 Slight  bleeding  --  frequent  suctioning  required.  Bleeding
threatens  surgical  ﬁeld  a  few  second  after  suction
removed
4  Moderate  bleeding  --  frequent  suctioning  required.
Bleeding  threatens  surgical  ﬁeld  directly  after  suction
removed
5  Severe  bleeding  --  constant  suctioning  required.  Bleeding
appears  faster  than  can  be  removed  by  suction.  Surgical
ﬁeld  severely  threatened  and  surgery  impossible
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he  neuromuscular  block  was  antagonized  with  neostigmine
0.05 mg  kg−1)  and  atropine  (0.01  mg  kg−1).  The  times  to
mergence from  anaesthesia  (extubation,  eye  opening  and
esponse to  simple  verbal  stimuli),  duration  of  surgery  and
otal remifentanil  consumption  were  recorded.  An  anaes-
hetist who  was  blinded  to  the  study  groups  conducted  the
ntire course  of  anaesthesia.  Intraoperative  bradycardia  and
ypotension were  deﬁned  as  a  HR  lower  than  45  beats/min
nd a MAP  value  less  than  50  mm  Hg,  respectively.  Patients
xperiencing bradycardia  or  hypotension  were  treated  with
tropine (0.5  mg)  or  intermittent  ephedrine  (5  mg).
Blinding was  achieved  by  requesting  an  anaesthetist  who
as not  involved  in  the  study  to  prepare  the  infusion  solu-
ions for  each  patient  according  to  the  computer-generated
andom numbers  and  groups  determined  at  the  beginning  of
he study.  The  solutions  were  labelled  with  the  patients’
ames only.  The  patient  name,  number  and  the  solution
repared were  recorded  by  this  anaesthetist.  The  solutions
ere then  given  to  the  anaesthetist  administering  the  anaes-
hesia.
ostoperative  management  and  evaluations
ll  patients  were  transferred  to  the  postanaesthesia  care
nit (PACU)  after  surgery  and  observed  for  3  h.  Pain  intensity
as evaluated  using  both  VAS  and  VRS.  Patients,  whose  VAS
cores were  ≥3  at  any  time,  received  an  IV  morphine  infusion
0.1 mg/kg  of  loading  dose,  1  mg  on  demand,  5  min  of  lock-
ut time)  by  a  PCA  device.  VAS  and  VRS  scores,  morphine
onsumption, time  to  ﬁrst  analgesia  and  side  effects  such
s sedation,  nausea,  vomiting,  and  respiratory  depression
ere recorded  at  the  indicated  time  intervals.  The  sedation
evel was  recorded  according  to  a  four-point  scale  (0  =  awake
nd alert,  1  =  mildly  sedated,  easy  to  arouse,  2  =  moderately
edated but  can  be  aroused,  3  =  deeply  sedated,  difﬁcult
o arouse).  Vomiting  was  treated  with  metoclopramide  IV
10 mg).  Respiratory  depression  was  deﬁned  as  a  ventila-
ory frequency  of  less  than  8  per  minute.  The  Aldrete  score
as evaluated  to  determine  the  time  to  discharge  from  the
ACU. At  the  end  of  3  h,  patients  with  an  Aldrete  score  of  ≥9
ere  discharged  from  the  PACU  after  being  directed  to  take
erioral  (P.O)  naproxen  sodium  for  analgesia,  if  needed.  At
he time  of  discharge,  all  patients  were  asked  two  questions:
1) what  was  the  last  thing  you  remember  after  entering  the
perating room?  and  (2)  do  you  recall  anything  from  your
peration?; to  determine  if  they  recalled  any  intraoperative
vents. Time  to  discharge  from  the  hospital  was  recorded.
he anaesthetist  who  observed  the  patients  during  surgery
lso observed  the  patients  in  the  PACU.  Both  patients  and
bservers were  blind  with  respect  to  treatment  groups.  On
he  second  day  after  surgery,  patients  were  interviewed
y telephone  to  evaluate  the  pain  intensity  and  analgesic
equirement after  discharge.
tatistical  analysis
tatistical  analyses  of  the  data  were  performed  using  the
tatistical Package  for  the  Social  Sciences  (SPSS)  version
1.5 programme  (SPSS  Inc.,  Chicago,  IL,  USA).  The  Shapiro
ilks’ test  was  used  to  determine  normal  distribution  for
ontinuous variables.  All  the  continuous  variables  were
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Table  2  Patient  and  surgical  characteristics.
Control  group  (n  =  30)  Esmolol  group  (n  =  30)  p-Value
Age  (yr) 29.1  (9.5) 27.4  (7.9)  0.445
Gender  (F/M)  19/11  21/9  0.584
Weight  (kg)  61.8  (11.8)  60.7  (8.7)  0.691
Height  (cm)  169  (8.9)  167  (6.6)  0.328
ASA  (I/II)  27/3  29/1  0.612
Duration  of  surgery  (min)  109  (35.1)  97  (27.8)  0.148
Duration  of  anaesthesia  (min)  126.6(36.9)  111  (29)  0.093
T  Remifentanil  used  (mg)  1.6  (1.3)  0.8  (0.5)  0.004a
The  emergence  times  (min)
Extubation 4.5  (2.3) 5.3(2)  0.568
Opening  eyes 5.3  (2.4) 6  (2.1) 0.602
Response to  orders  6  (2.4)  6.3  (2)  0.856
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sia (p  =  0.001,  p  = 0.034  and  p  = 0.016,  respectively  for  VAS
scores; p  =  0.033,  p  =  0.016  and  p  = 0.022,  respectively  for
VRS scores).
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Figure  1  MAP  (mm  Hg)  during  anaesthesia.
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a p < 0.05; statistically signiﬁcant.
resented  as  median  and  standard  deviation.  The  ordinal
ariables were  presented  as  median  (inter-quartile  range)
nd categorical  variables  were  presented  as  percentage  (%).
he mean  values  of  groups  were  compared  using  Student’s
 or  Mann--Whitney  U  tests.  Repeated  SAP,  DAP,  MAP,  SpO2
nd  HR  values  were  compared  using  the  Bonferroni  multi-
le comparisons  test  within  the  groups  and  between  groups.
ariance analysis  was  used  for  repeated  measurements.
ecause repeated  variables  showed  signiﬁcant  change,  the
easurement time  causing  this  change  was  determined
or categorical  comparisons  using  Chi-squared  and  Fisher’s
xact tests.  The  Mann--Whitney  U  test  was  used  to  compare
onparametric variables.  Statistical  signiﬁcance  was  set  at
 <  0.05.
esults
ll  60  patients  enrolled  in  the  study  were  evaluated  for
tatistical analysis  and  all  the  analyses  were  performed
ccording to  the  original  groups.  All  patients  were  evalu-
ted for  the  analgesic  and  anaesthetic  effects  of  esmolol
nd no  patients  were  excluded  after  randomization.  Patient
haracteristics, duration  of  surgery  and  anaesthesia,  quan-
ity of  remifentanil  used,  the  emergence  times  from  the
nd of  anaesthesia  for  the  two  groups  are  shown  in  Table  2.
emifentanil used  during  anaesthesia  was  signiﬁcantly  lower
n the  esmolol  group  (p  =  0.004).  There  were  no  differ-
nces in  patient  characteristics,  duration  of  anaesthesia  and
urgery and  the  emergence  times  from  the  end  of  anaesthe-
ia between  two  groups.
The MAP  during  anaesthesia  is  shown  in  Fig.  1.  There  was
o signiﬁcant  difference  between  two  groups  with  regard  to
AP during  anaesthesia.  The  MAP  showed  ﬂuctuations  from
aseline value  in  both  groups.
The  HR  during  anaesthesia  is  shown  in  Fig.  2.  The  HR  at
0th, 80th  and  90th  minutes  after  intubation  was  higher  in
he esmolol  group  (p  =  0.035,  p  =  0.027  and  p  =  0.017,  respec-
ively). The  HR  was  generally  higher  during  surgery  in  the
smolol group  but  it  was  not  statistically  signiﬁcant.  The  HR
howed ﬂuctuations  from  baseline  value  in  both  groups.
The  BIS  values  are  shown  in  Fig.  3.  There  were  no  sig-
iﬁcant differences  between  two  groups  with  regard  to  BIS
F
nalues  during  anaesthesia.  There  were  also  no  signiﬁcant
ifferences from  the  baseline  value  in  both  groups.
VAS  and  VRS  scores  are  shown  in  Figs.  4  and  5,  respec-
ively. The  VAS  and  VRS  scores  were  signiﬁcantly  lower  in
he esmolol  group  at  1  and  20  min  and  1  h after  anaesthe-be
for
e
aft
er in in in
igure  2  HR  (beats  min−1)  during  anaesthesia.  *p  <  0.05;  sig-
iﬁcant inter-group  differences.
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Figure  3  BIS  values  during  anaesthesia.
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Time  to  ﬁrst  analgesia  and  discharge  from  PACU,  Aldrete
scores, quantity  and  percentage  of  IV  morphine  and  anal-
gesic used  after  discharge  and  the  incidence  of  side  effects
in both  groups  are  shown  in  Table  3.  Time  to  ﬁrst  analge-
sia was  signiﬁcantly  longer  in  the  esmolol  group  (p  =  0.001).
Total morphine  consumption  and  the  number  of  patients  who
received IV  morphine  were  signiﬁcantly  lower  in  esmolol
group (p  =  0.011  and  p  =  0.005,  respectively).
u
s
Table  3  Patients’  data  in  postoperative  period.
Control  group  (n  =  30)  
Time  to  ﬁrst  analgesia  (min)  43.8  (60.8)  
Morphine  used  (mg)  12.9  (8.7)  
Morphine  usage  (%)  86.7  
Time  to  discharge  (min)  202.8  (38)  
Aldrete  score  (9/10)  4/26  
Analgesic  at  home  (tablets)  3.6  (2.5)  
Analgesic  at  home  (%)  80  
Side  effects
Nausea  8  
Vomiting  4  
Sedation  scores  (0/1)  4/26  
Values are mean (SD) or number.
a p < 0.05; statistically signiﬁcant.igure  5  VRS  scores  in  the  postoperative  period.  *p  <  0.05;
tatistically signiﬁcant.
iscussion
n  this  study  we  found  that  esmolol  shows  a  postopera-
ive analgesic  effect  when  administered  intraoperatively  in
eptorhinoplasty patients.  Esmolol  reduced  the  postopera-
ive VAS  and  VRS  scores,  together  with  elongating  the  time
o ﬁrst  analgesia  and  reducing  both  the  total  IV  morphine
onsumption and  the  number  of  patients  who  needed
orphine. Also,  the  amount  of  remifentanil  used  during
naesthesia was  signiﬁcantly  lower  in  the  esmolol  group.
Previous  studies  focused  on  the  effect  of  -blocker
sage upon  anaesthesia  and  postoperative  pain  manage-
ent have  suggested  that  -antagonists  reduce  anaesthetic
equirements during  anaesthesia5 and  inhalation  anaes-
hetic minimum  alveolar  concentration  (MAC),6 and  improve
arly postoperative  recovery.11
The  speciﬁc  mechanism  by  which  -blockade  potentiates
he analgesic  effect  of  an  opioid  remains  controver-pon postsynaptic  inhibition  via  G  protein-coupled  potas-
ium channels  or  via  the  pre-synaptic  inhibition  of
Esmolol  group  (n  =  30)  p-Value
108  (81.6)  0.001a
7.1  (8.4)  0.011a
53.3  0.005a
189.5  (11.5)  0.071
3/27  0.688
2.6  (2.2)  0.92
73.3  0.542
6  0.542
4  1.000
2/28  0.389
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eurotransmitter  release  through  the  regulation  of  voltage-
ated Ca2+ channels;  such  a  pathway  underlies  the
ociceptive effect  of  clonidine.12 Hageluken  and  colleagues
emonstrated that  -adrenergic  antagonists  activated  G-
roteins  in  isolated  cell  membranes  and  it  was  suggested
hat this  was  the  mechanism  of  central  analgesia.13
Esmolol  has  been  postulated  to  reduce  anaesthetic
equirements  via  a  direct  antinociceptive  property  in  a  vari-
ty of  experimental  studies,  suggesting  the  potential  to
ecrease the  intraoperative  anaesthetic  requirements.8,14 In
nimals esmolol  provided  analgesia  and  reduction  of  cardio-
ascular responses  to  pain  in  the  absence  of  anaesthesia.9
Another  mechanism  that  may  signiﬁcantly  contribute  to
he anaesthetic-sparing  involves  decreased  excitatory  stim-
lation of  central  nervous  system  effector  sites  of  hypnosis
nd somatic  response.  In  this  case,  peripheral  interrup-
ion of  -adrenergic  autonomic  pathways  decreases  afferent
nput and  anaesthetic  requirements.15 The  clinical  utility  of
his effect  was  demonstrated  by  Zaugg  et  al.11 in  a  study  with
lderly surgical  patients  undergoing  non-cardiac  surgery.
re- and  postoperative  atenolol  and  high  dose  intraoper-
tive atenolol  decreased  requirements  for  intraoperative
entanyl and  postoperative  morphine.  Chia  et  al.7 suggested
hat perioperative  esmolol  administration  reduced  the  intra-
perative  use  of  isoﬂurane  and  fentanyl  as  well  as  reducing
orphine consumption  for  3  days  postoperatively  in  patients
ndergoing abdominal  total  hysterectomy.
Several  studies  have  suggested  that  sympatholytic
rugs may  be  alternative  to  opioids  in  treating  acute
ntraoperative haemodynamic  responses.  It  was  reported
hat in  elderly  patients  undergoing  noncardiac  surgery,
erioperative -blockade  with  atenolol  improved
aemodynamic  stability,  reduced  the  opioid  analgesic
equirement and  contributed  to  a  faster  early  recovery.11
n  a  previous  study,  it  was  suggested  that  perioperative
-antagonist administration  was  an  alternative  to  remifen-
anil in  maintaining  intraoperative  stable  haemodynamics
ith similar  side  effects.16 This  was  also  the  case  in  our
tudy, with  no  statistically  signiﬁcant  difference  between
roups with  respect  to  intraoperative  HR  and  MAP,  demon-
trating that  esmolol  successfully  replaced  a  role  classically
erformed by  remifentanil.
Some studies  suggested  that  administration  of  esmolol
ttenuated the  cardiovascular  response  to  perioperative
timuli. Miller  et  al.1 suggested  that  a  bolus  dose  of  esmolol
ombined with  a  low  dose  of  narcotic  resulted  in  effective
ontrol of  haemodynamic  response  to  tracheal  intubation.
n different  studies,  it  was  demonstrated  that  a  single  bolus
ose of  esmolol  effectively  attenuated  HR  and  systolic  blood
ressure increases  produced  by  laryngoscopy  and  tracheal
ntubation.17,18
Similar  to  these  studies,  esmolol  attenuated
aemodynamic  responses  to  perioperative  stimuli  such
s tracheal  intubation,  incision  and  extubation  and  there
ere no  differences  between  groups  in  our  study  with
espect to  haemodynamic  responses.
Adequate  depth  of  anaesthesia  as  indicated  by  the  BIS
as achieved  in  a  group  of  elderly  patients,  using  high
ose atenolol  and  a  restricted  amount  of  anaesthesia.11n  parallel  to  this  study  despite  remifentanil  requirements
eing signiﬁcantly  lower,  anaesthesia  was  still  adequate  as
ndicated by  BIS  in  the  esmolol  group  and  no  recall  was
d
v
uN.  Celebi  et  al.
een  in  either  of  the  groups  in  our  study.  Also,  noxious
timuli during  general  anaesthesia  causes  an  increase  in
IS as  well  as  tachycardia,  hypertension  and  movement.19,20
revious  studies  assessing  the  effectiveness  of  esmolol  in
lunting the  haemodynamic  responses  induced  by  tracheal
ntubation failed  to  monitor  electrical  activity  of  the  brain.
nly a  few  studies  have  evaluated  the  effect  of  interac-
ion between  -adrenergic  antagonists  and  anaesthetics  on
IS.11,16 In  2001  Johansen  suggested  that  perioperative  infu-
ion of  esmolol  decreased  BIS  values  and  increased  burst
uppression ratio.21 In  2002,  Menigaux  and  colleagues  sug-
ested that  esmolol  attenuated  haemodynamic  and  somatic
esponses to  laryngoscopy  and  orotracheal  intubation,  and
lso prevented  BIS  arousal  reactions  in  patients  anaes-
hetized with  propofol.22 In  our  study  esmolol  prevented  BIS
ncreases in  response  to  noxious  stimuli  including  tracheal
ntubation, incision  and  tracheal  extubation  as  well  as  blunt-
ng haemodynamic  responses  in  relation  to  these  stimuli.
nly one  patient  in  both  groups  demonstrated  signiﬁcant
achycardia and  hypertension  associated  with  an  increase  in
IS. The  clinical  importance  of  this  ﬁnding  is  that  esmolol
ay have  the  potential  to  replace  anaesthetic  drugs  that
re given  for  the  sole  purpose  of  blunting  haemodynamic
esponses.
Titration of  anaesthetics  to  HR  and  blood  pressure  with-
ut administration  of  -adrenergic  antagonists  may  lead  to
rolonged recovery  from  anaesthesia  as  a  result  of  ‘rel-
tive overdosing’  with  administered  anaesthetics  and/or
nalgesics. Faster  recovery  from  anaesthesia  was  reported
n patients  receiving  propranolol.23 It  was  shown  that  the
xtubation time  and  recovery  in  the  PACU  were  signiﬁ-
antly faster  in  patients  treated  with  intra-  or  perioperative
tenolol.11 In  contrast  to  these  studies,  there  were  no
ifferences in  extubation  time  and  recovery  from  anaes-
hesia between  groups  in  our  study.  In  these  studies  the
atients were  under  chronic  -adrenergic  antagonist  treat-
ent in  the  preoperative  period  or  high  dose  atenolol
as administered  intraoperatively.  However  none  of  our
atients were  receiving  -adrenergic  antagonists  chron-
cally and  esmolol  was  not  administered  in  high  dose,
uggesting a  relationship  between  the  chronicity  of  use  of
-adrenergic antagonists  and  the  time  to  recovery  from
naesthesia.
There are  some  limitations  to  this  study.  The  patients
n the  esmolol  group  received  remifentanil  as  an  analgesic
uring the  operation.  BIS  values  were  recorded  to  deter-
ine wakefulness  of  patients.  Although  BIS  values  during
urgery were  similar  between  groups,  analgesia  is  a  differ-
nt concept  from  anaesthesia.  The  esmolol  administered
o patients  may  have  partially  masked  the  classical  hyper-
ension and  tachycardia  responses  that  are  associated  with
ain. However,  analgesic  administration  was  not  omitted
n the  esmolol  group,  despite  being  consumed  at  a  lower
ose.
In conclusion,  esmolol  reduced  intraoperative  remifen-
anil and  postoperative  morphine  consumption;  but  it  had  no
ffect on  depth  of  anaesthesia.  We  suggested  that  esmolol
ay possess  analgesic  properties,  and  because  it  is  capa-
le of  effectively  controlling  tachycardia  and  hypertension
uring surgery,  it  may  also  demonstrate  the  beneﬁt  of  pro-
iding a  faster  recovery  with  fewer  side  effects  for  patients
ndergoing ambulatory  surgery.
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